CDH17 knockdown in AGS cells reduced their tumorigenicity in vivo and were used for targeting CDH17 for gastric cancer therapy.
A. Representative examples of tumors formed in nude mice following injection of shCDH17 cells in the left dorsal flanks. AGS and Mock cells were injected into the right, respectively. Line chart illustrates that the changes in volume of the subcutaneous tumors, shRNA vs. Mock,*p<0.05. B. Effect of CDH17 shRNA suppression on the growth of subcutaneous tumors in nude mice. Subcutaneous tumors were induced in nude mice by injection of AGS cells; treatment involved an intratumoral injection of Mock reagents (non-targeted RNAi vector) or shCDH17 regimen at a dose of 109 viral particle/injection at the tumor site of animals (n = 3). Photographs illustrate the subcutaneous tumor produced by Mock and shCDH17 in nude mice. The volume of tumor induced in nude mice was measured among the three experimental groups after 35 days. IHC pictures demonstrate that CDH17 expression decreased in shRNA treated mice. Original magnification, ×400. Line chart illustrates that the changes in volume of the subcutaneous tumors. shRNA vs. Mock, ***p<0.001.